Gathering the record
Relay is organizing the evidence and source boundaries.
GIP-receptor-antagonist antibody / GLP-1-agonist peptide conjugate
An experimental weight-loss drug designed to work with less frequent injections.
Evidence is explained by question. Dosing references show their own check dates.
60-second overview
Why people look into it, what studies found, and what is still unknown.
Educational information only. Evidence reviewed through July 31, 2026. Published studies, sponsor announcements, and trials without results are labeled separately. Evidence gaps apply to the specific finding beside them.
Research questions
Each label shows how much evidence supports that question.
What studies show
A peer-reviewed 592-participant randomized Phase 2 obesity trial with and without type 2 diabetes, supported by Phase 1 pharmacokinetic research and active Phase 3 trials.
A complex antibody conjugate cannot be evaluated or handled like a generic research peptide.
It is not a standard peptide, not a dual GIP/GLP-1 agonist, and not mechanistically interchangeable with tirzepatide.
The strongest selected regimens approached 20% mean reduction in participants without diabetes.
The diabetes evidence is direct, though the weight response was smaller than in participants without diabetes.
Lower starting doses and escalation were studied to reduce early adverse effects.
The broad MARITIME program is confirmatory; it does not yet prove approval or outcome benefit.
Risks & unknowns
Gastrointestinal tolerability and initiation strategy are central to MariTide's benefit-risk profile.
Controlled human evidenceNo approved initiation or maintenance schedule exists.
Open sourceThe available information does not reliably show how often particular side effects occur.
Evidence boundaryUnder-detected or under-reported events must not be described as rare.
Relay has not verified which side effects led people to stop treatment in studies.
Evidence boundaryThis is an evidence gap, not proof that discontinuations did not occur.
Relay has not verified a compound-specific warning summary for this profile.
Evidence boundaryInvestigational; Phase 3 MARITIME development Long-term safety and immunogenicity, optimal initiation strategy, cardiovascular outcomes, weight maintenance, performance across obesity complications, and whether Phase 2 efficacy replicates in Phase 3.
This profile does not contain verified, product-specific emergency instructions.
Evidence boundaryRelay does not infer emergency guidance from study discontinuations, mechanism, or incomplete adverse-event reporting.
Dosing references
Each table labels its source and applies only to the named route, product, or study. An online example or community report is not an approved dose.
Amounts reported in a human study. A studied amount is not automatically an approved dose or a recommendation for an individual.
The trial included separate obesity cohorts with and without type 2 diabetes.
| Study pattern | Amount | Interval |
|---|---|---|
| Groups without escalation | 140, 280, or 420 mg | Every 4 weeks |
| Separate obesity-only group | 420 mg | Every 8 weeks |
| Separate escalation groups | 420 mg target | Every 4 weeks; 4- or 12-week escalation |
Every 4 weeks and every 8 weeks are different trial arms. The milligram amounts belong to this peptide–antibody conjugate and cannot be compared directly with other GLP-1 drugs.
MariTide · randomized Phase 2 trial Primary article · Methods / interventionThis reference checked Oct 20, 2026. The full-profile review date is shown at the top.This source does not establish a mixing volume or storage period for independently sourced powder. Use formulation-specific instructions; the study amount alone is not a reconstitution recipe.
Concentration = total mass ÷ final volume. The calculator performs user-entered math; it does not choose a dose or diluent.
Open concentration calculatorStarting dose: the amount used at the beginning of the named label schedule or trial.
Maintenance: the ongoing amount described by that product label.
Trial target: the amount assigned to a study group. Different groups may stop increasing at different targets.
A published Phase 2 trial studied MariTide in adults with overweight or obesity, including separate cohorts with and without type 2 diabetes.
Population: Adults with overweight or obesity, with or without type 2 diabetes
Design: Randomized, double-blind, placebo-controlled dose-ranging trial
Mechanisms
Maridebart cafraglutide (MariTide; AMG 133) is engineered by conjugating two GLP-1 receptor agonist peptide moieties to a fully human monoclonal antibody that antagonizes GIPR. This creates a mechanistically unusual GLP-1 agonist/GIP antagonist with monthly or less-frequent exposure in clinical development. In a 592-participant Phase 2 trial, participants without diabetes had mean weight reductions approaching 20% in selected regimens at 52 weeks, while the type 2 diabetes cohort had substantial weight and HbA1c reductions. Gastrointestinal events, loading-dose tolerability, antibody-like pharmacokinetics, and limited long-term data remain important. Multiple Phase 3 MARITIME trials are evaluating chronic weight management and obesity-related conditions, but approval and clinical outcome-event benefits are unproven.
A plausible mechanism can explain why a study was attempted. It does not prove that the compound improves a human outcome.
Research reference
A reference for the studies, populations, and routes behind this profile.
A substantial peer-reviewed Phase 2 trial and early pharmacology support active Phase 3 programs.
Research depth describes how large and mature the overall record is. It does not tell you whether the results were positive.
The weight signal is strong; long-term safety, immunogenicity, outcomes, and pivotal replication remain unresolved.
Confidence describes how reliable and consistent the conclusions are. It can be high for one outcome and low for another.
The strongest evidence type shows what the best-supported conclusions are actually based on.
Human findings are more directly relevant than animal or laboratory results, but they still apply only to the populations and outcomes studied.
Route-specific record
These are exposures used in cited research for a specific route and population—not an instruction for an individual.
Half-life describes how long it takes the measured amount in the body to fall by half. It is not a dosing recommendation.
Evidence can change by administration method. Findings from one route should not automatically be applied to another.
Evidence boundary: The study compared several research arms and initiation approaches rather than one transferable schedule. Phase 2 findings do not establish approval, long-term outcomes, or an independent-product handling standard. Amounts shown describe cited research exposure—not a dosage recommendation.
Studies
Study arms are reported for transparency. They describe what researchers did in a defined record and do not transfer across identities, routes, formulations, or populations.
A later trial phase can ask a more mature question, but it does not guarantee a positive result, regulatory approval, or relevance outside the studied population.
Randomized, double-blind, placebo-controlled dose-ranging trial
Adults with overweight or obesity, with or without type 2 diabetes
Selected regimens produced mean weight reductions approaching 20% without diabetes and substantial weight and HbA1c reductions in the diabetes cohort.
Study administration: Monthly or every-eight-week maridebart cafraglutide regimens or placebo
Limitations: Dose groups and estimands differ, loading-dose gastrointestinal effects were important, and Phase 2 cannot establish long-term outcomes or an approved regimen.
Receptor pharmacology, animal models, and early human translation
Laboratory systems, animal models, and early clinical participants
The program established simultaneous GLP-1 agonism and GIPR antagonism with prolonged biologic exposure.
Study administration: GIPR-antagonist antibody conjugated to two GLP-1 analogues
Limitations: Preclinical efficacy and receptor logic cannot predict the long-term human benefit-risk profile.
Randomized placebo-controlled trial
Adults with obesity or overweight and type 2 diabetes
A dedicated Phase 3 trial is evaluating the population that generally showed less weight loss in Phase 2.
Study administration: Maridebart cafraglutide or placebo
Limitations: No completed pivotal results were available.
Randomized, double-blind, placebo-controlled chronic weight-management trial
Adults with obesity or overweight
The MARITIME program is testing whether Phase 2 weight effects replicate in larger pivotal populations.
Study administration: Maridebart cafraglutide or placebo
Limitations: Completed Phase 3 results were not available at the cutoff.
Community
Built by the community
Every structured report adds useful context about research setup, outcomes, and unwanted effects as the community dataset grows.
Publicly anonymous by default. Your account keeps reports editable and helps reduce duplicate submissions.Sources
2026-05-01
2025-06-23 · PMID 40549887 · DOI 10.1056/NEJMoa2504214
2025-05-30 · NCT06987695
2025-03-06 · NCT06858878
2024-02-05 · PMID 38316982